Cronos Group (NASDAQ:CRON) Upgraded to “Buy” at Wall Street Zen

Cronos Group (NASDAQ:CRON) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday, Wall Street Zen reports.

A number of other research analysts have also recently weighed in on CRON. TD Securities reiterated a “buy” rating on shares of Cronos Group in a research report on Monday, September 28th. Zacks Research upgraded Cronos Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 22nd. Finally, Weiss Ratings upgraded Cronos Group from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Cronos Group presently has an average rating of “Buy” and a consensus price target of $2.30.

Cronos Group Stock Down 3.0%

Shares of CRON stock opened at $3.61 on Friday. The stock has a market capitalization of $1.33 billion, a P/E ratio of 30.27 and a beta of 0.96. Cronos Group has a fifty-two week low of $2.28 and a fifty-two week high of $3.91. The stock has a 50-day simple moving average of $3.31 and a 200 day simple moving average of $2.88.

Cronos Group (NASDAQ:CRON) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. The business had revenue of $63.45 million during the quarter, compared to analysts’ expectations of $51.15 million. Cronos Group had a net margin of 39.08% and a return on equity of 4.85%. On average, sell-side analysts anticipate that Cronos Group will post 0.12 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CRON. Cibc World Market Inc. purchased a new position in shares of Cronos Group during the 2nd quarter valued at $3,820,000. Pillsbury Lake Capital LLC acquired a new stake in Cronos Group during the second quarter worth approximately $2,252,253. Parallax Volatility Advisers L.P. bought a new position in Cronos Group in the second quarter valued at about $834,000. Bank of America Corp DE acquired a new position in Cronos Group in the second quarter valued at approximately $438,000. Finally, Legal & General Group Plc purchased a new position in shares of Cronos Group during the second quarter valued at approximately $485,000. 8.71% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Cronos Group

Here are the key news stories impacting Cronos Group this week:

• Positive Sentiment: Q3 net revenue rose 73% year over year on an organic, constant-currency basis, with the company reporting record net revenue, gross profit and adjusted EBITDA. Revenue of $63.45 million and earnings of $0.04 per share also exceeded analyst estimates of $51.15 million and $0.03, respectively. Cronos Group Reports 2026 Third Quarter Results
• Positive Sentiment: Growth was broad-based: Cronos posted record Canadian sales, a record quarter in Germany, and its 11th consecutive quarter of record net revenue in Israel. Its Spinach brand retained the top position in Canadian vapes and edibles, while the Canatolar acquisition expands its European reach. Q3 2026 Earnings Call Highlights
• Neutral Sentiment: The company said it reduced its share count, which can support per-share results, though the available reports do not quantify the effect. Cronos Group Reports 2026 Third Quarter Results
• Negative Sentiment: Despite beating estimates, Q3 earnings of $0.04 per share were below the $0.07 reported a year earlier. A separate valuation discussion also notes that the stock’s 93% three-year gain puts more focus on whether current earnings justify its valuation. Cronos Group Stock Looks Hard To Call Following Its 93% Run

About Cronos Group

Cronos Group Inc is a Canadian cannabinoid company focused on developing, producing and commercializing cannabis and cannabis-derived consumer products. The company serves adult-use and medical cannabis markets through a portfolio of brands and sells products such as dried flower, pre-rolls, vaporizers, edibles, oils and other cannabis formats, subject to applicable regulations.

Its brand portfolio has included Spinach, which is positioned primarily in the adult-use cannabis market, as well as Lord Jones and PEACE NATURALS.